Insilico, which uses AI to accelerate drug discovery, says early data shows rentosertib, a drug whose structure was generated with AI's help, could slow aging (Cade Metz/New York Times)

Insilico, a company leveraging AI for drug discovery, has announced early data suggesting that rentosertib, a drug whose structure was generated with AI's help, could potentially slow aging. Originally developed to treat a chronic lung disease, this drug candidate's development was accelerated through the application of artificial intelligence, as reported by Cade Metz in The New York Times.